NEWSROOM
Press Releases by Agendia
News
Press Releases
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint and BluePrint Across Breast Cancer Patient Populations
IRVINE, CA, AMSTERDAM, NETHERLANDS – 30 November 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Read More
Agendia’s MammaPrint Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
CMS established the 2018 payment rate for MammaPrint’s new CPT code 81521 thus securing continued access to MammaPrint for Medicare/Medicaid beneficiaries The new determination and increased allowance follows an impressive Q3 which saw MammaPrint’s U.S. Read More
AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the Read More
New Study Published in JAMA Oncology Shows MammaPrint Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay
Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay’s intermediate range Physicians changed their treatment decisions in approximately 34% of all cases and in 76% Read More
Breast Cancer is the Most Feared Cancer Among Women in Germany, Although Less than Half are Aware of the Benefits of Genomic Testing
KANTAR survey: Only 40% of breast cancer patients know the benefits of genomic testing IRVINE, CA and AMSTERDAM, 9 October 2017 – Breast cancer is the most feared type of cancer among women in Germany, Read More
Breast Cancer – Let’s Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities
Flash Mob for Breast Cancer Empowerment, in partnership with the Tigerlily Foundation, takes place at the Lincoln Memorial in Washington, DC on Saturday 14 October International events including support of Susan G. Komen Race for Read More
10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment
First time 10-year prospective outcome data confirms clinical utility of MammaPrint for lymph node-negative and lymph node-positive patients MINDACT sub-study shows that even tumors less than 1cm in size can be aggressive with 24% reclassified Read More
